Research on Identifying and Treatment Prognosis of Chronic Rhinosinusitis Based on Image and Sequencing Data
Study Details
Study Description
Brief Summary
This project focuses on researching chronic rhinosinusitis in patients, employing image processing techniques and molecular biology methods to jointly determine the research objectives:
-
Investigating heterogeneity.
-
Developing an intelligent assessment model.
-
Creating a visual tool for diagnosis and prognosis.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
-
Investigating the heterogeneity of chronic rhinosinusitis: the project will utilize high-throughput information from various sources such as radiology, pathology, and proteomics to gain insights into the multi-dimensional and big data aspects of chronic rhinosinusitis. By analyzing this data, the study aims to identify and understand the different subtypes with more precise and personalized treatment approaches.
-
Developing an intelligent assessment model: using artificial intelligence algorithms, the project will analyze multi-omics data gathered from the research. The goal is to establish an intelligent assessment model that can accurately interpret the data and provide valuable insights into chronic rhinosinusitis.
-
Creating a visual tool for diagnosis and prognosis: the project seeks to integrate multi-omics information to establish an AI model for typing and prognostic prediction. By achieving these research objectives, this project aspires to enhance the understanding of chronic rhinosinusitis and contribute to the development of more precise, personalized, and effective treatment strategies for patients suffering from this condition.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Control Following the efficacy assessment method outlined in the 2020 EPOS guidelines, the treatment outcomes of chronic sinusitis are categorized as "controlled" or "uncontrolled." Clinical reference evaluation criteria include: nasal congestion, rhinorrhea, facial pain, reduced sense of smell, sleep disturbances, the need for ongoing medication maintenance and the abnormal nasal endoscopy findings, .If there are no three or more symptoms rated five or higher, the patient's chronic sinusitis is considered controlled. |
Procedure: endoscopic sinus surgery
Open the sinus ostium, improve anatomical issues and remove the diseased tissue.
Other Names:
|
| Uncontrol Following the efficacy assessment method outlined in the 2020 EPOS guidelines, the treatment outcomes of chronic sinusitis are categorized as "controlled" or "uncontrolled." Clinical reference evaluation criteria include: nasal congestion, rhinorrhea, facial pain, reduced sense of smell, sleep disturbances, the need for ongoing medication maintenance and the abnormal nasal endoscopy findings, . The classification is based on the number and severity of these symptoms,and patients with three or more symptoms rated five or higher are considered to have uncontrolled disease |
Procedure: endoscopic sinus surgery
Open the sinus ostium, improve anatomical issues and remove the diseased tissue.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Change from baseline at months 12 in visual analogue scale (VAS) after surgical intervention [12month]
The VAS for rhinosinusitis was used to evaluate the total disease severity. The participants were asked to indicate on a 10 centimeters (cm) VAS the answer to the question, "How troublesome are your symptoms of your rhinosinusitis?" The range of the VAS was from 0 (not troublesome) to 10 (worse thinkable troublesome) of troublesome, where higher score indicated worse thinkable troublesome.
Secondary Outcome Measures
- Change from baseline at months 1, 3, 6 and 12 in 22-item sino-nasaloutcome test (SNOT-22) scores after surgical intervention [1month, 3month, 6month, 12month]
The SNOT-22 is a validated questionnaire that was used to assess the impact of chronic rhinosinusitis on health-related quality of life (HRQoL). It is a 22 item questionnaire with each item assigned a score ranging from 0 (no problem) to 5 (problem as bad as it can be). The total score may range from 0 (no disease) to 110 (worst disease), lower scores representing better health related quality of life.
- Revision surgery rate [12month]
The rate of reoperation in each group after surgery
- Symptom duration [1month, 3month, 6month, 12month]
The time of duration of major symptoms of postoperative patients
- Change from baseline at months 1, 3, 6 and 12 in nasal endoscopic score after surgical intervention [1month, 3month, 6month, 12month]
Endoscopic result is scored according to Lund-Kennedy system, with the assessment of nasal polyp (NP), edema, nasal discharge, scarring and crusting. Items including edema, nasal discharge, scarring and crusting score 0 for no problem, 1 for mild abnormalities and 2 for severe abnormalities. NP score is graded and based on NP size recorded as the sum of the right and left nostril scores with a range of 0-8; higher scores indicate worse status. Individual score ranges from 0 (no polyps) to 4 (large polyps causing almost complete congestion/ obstruction of the inferior meatus) within each nostril.
- Postoperative medication [1month, 3month, 6month, 12month]
The duration and dose of postoperative medication needed to relieve symptoms
Other Outcome Measures
- Changes from baseline at months 1, 3, 6 and 12 in molecular indices of nasal lavage fluid by Bio-plex [1month, 3month, 6month, 12month]
Investigate the change of inflammation molecular biomarkers using sample of nasal lavage fluid or mucosal lesion tissue. Biomarkers including interleukin 9, monocyte chemoattractant protein-1, macrophage inflammatory protein-1β, macrophage inflammatory protein-1α and chemokine (C-C motif ) ligand 17 in nasal lavage fluid by Bio-plex (Bio-Rad, Hercules, CA, USA) at months 1, 3, 6 and 12 were detected to compare the changes of molecular indices relative to baseline.
- Changes from baseline at months 1, 3, 6 and 12 in molecular indices of nasal lavage fluid by ELISA [1month, 3month, 6month, 12month]
Investigate the change of inflammation molecular biomarkers using sample of nasal lavage fluid or mucosal lesion tissue. Biomarkers including Immunoglobulin (Ig) E in nasal lavage fluid by enzyme linked immunosorbent assay (ELISA) at months 1, 3, 6 and 12 were detected to compare the changes of molecular indices relative to baseline.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
oral glucocorticoid, and intranasal steroid spray and steroid irrigation treatment were discontinued at least 3 months and 1 month before surgery, respectively;
-
without acute asthma episode or acute upper airway infection within 1 month before surgery;
-
not under allergen immunotherapy or biologic treatment.
Exclusion Criteria:
-
fungal sinusitis;
-
antrochoanal polyps;
-
cystic fibrosis, vasculitis, primary ciliary dyskinesia, or immunodeficiency;
-
odontogenic maxillary sinusitis;
-
patients with history of craniocerebral trauma or sinonasal tumours.
-
insufficient CT quality (e.g., metal artifacts, motion artifacts, and lack of intact CT scan of sinuses);
-
slice thickness more than 2.5 mm.
-
women must not be pregnant, or breast-feeding;
-
patients with serious metabolic, cardiovascular, autoimmune, neurology, blood, digestive, cerebrovascular, or respiratory system disease, or any disease interfering with the evaluation of results or affecting subjects safety are excluded, such as glaucoma and tuberculosis;
-
patients with emotional or mental problems are excluded;
-
patients unsuitable for inclusion based on judgement of researchers are excluded;
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Department of ENT, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology | Wuhan | Hubei | China | 430030 |
Sponsors and Collaborators
- Zheng Liu
Investigators
- Principal Investigator: Zheng Liu, Doctor, Huazhong University of Science and Techology
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- ENT-Radiology-01